Successful intrauterine treatment of a patient with cobalamin C defect.

Trefz FK; Scheible D; Frauendienst-Egger G; Huemer M; Suomala T; Fowler B; Haas D; Baumgartner MR

doi:10.1016/j.ymgmr.2016.01.005

Back

Journal article

Successful intrauterine treatment of a patient with cobalamin C defect.

Trefz FK University Children's Hospital, Department of Metabolism and Pediatric Medicine, Heidelberg, Germany.
Scheible D Klinik für Kinder und Jugendmedizin Reutlingen, Germany.
Frauendienst-Egger G Klinik für Kinder und Jugendmedizin Reutlingen, Germany.
Huemer M Department of Paediatrics, Landeskrankenhaus Bregenz, Austria; University Children's Hospital Zürich, Switzerland.
Suomala T University Children's Hospital Zürich, Switzerland.
Fowler B University Children's Hospital Zürich, Switzerland.
Haas D University Children's Hospital, Department of Metabolism and Pediatric Medicine, Heidelberg, Germany.
Baumgartner MR University Children's Hospital Zürich, Switzerland.

2016-03-26

Published in:

Molecular genetics and metabolism reports. - 2016

English Cobalamin C (cblC) defect is an inherited autosomal recessive disorder that affects cobalamin metabolism. Patients are treated with hydroxycobalamin to ameliorate the clinical features of early-onset disease and prevent clinical symptoms in late-onset disease. Here we describe a patient in whom prenatal maternal treatment with 30 mg/week hydroxycobalamin and 5 mg/day folic acid from week 15 of pregnancy prevented disease manifestation in a girl who is now 11 years old with normal IQ and only mild ophthalmic findings. The affected older sister received postnatal treatment only and is severely intellectually disabled with severe ophthalmic symptoms. This case highlights the potential of early, high-dose intrauterine treatment in a fetus affected by the cblC defect.

Language